Biogen (NASDAQ:BIIB – Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of $3.99 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Biogen Price Performance
Shares of Biogen stock opened at $248.63 on Tuesday. The firm has a fifty day simple moving average of $256.85 and a 200-day simple moving average of $277.06. The company has a current ratio of 3.27, a quick ratio of 2.86 and a debt-to-equity ratio of 0.43. Biogen has a 1-year low of $233.76 and a 1-year high of $319.76. The stock has a market capitalization of $36.01 billion, a price-to-earnings ratio of 13.53, a PEG ratio of 2.59 and a beta of 0.10.
Insider Transactions at Biogen
In other news, insider Priya Singhal sold 431 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $269.43, for a total value of $116,124.33. Following the completion of the sale, the insider now owns 3,354 shares of the company’s stock, valued at approximately $903,668.22. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.60% of the company’s stock.
Institutional Investors Weigh In On Biogen
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. StockNews.com began coverage on shares of Biogen in a research report on Thursday, October 5th. They set a “buy” rating on the stock. Truist Financial reduced their price target on shares of Biogen to $340.00 and set a “buy” rating on the stock in a research report on Tuesday, August 8th. Wells Fargo & Company reduced their price target on shares of Biogen from $350.00 to $343.00 and set an “overweight” rating on the stock in a research report on Monday, August 7th. Wedbush cut their target price on shares of Biogen from $270.00 to $266.00 and set a “neutral” rating on the stock in a research report on Thursday, October 26th. Finally, Morgan Stanley cut their target price on shares of Biogen from $381.00 to $361.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 11th. Four investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $328.21.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
- Five stocks we like better than Biogen
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These 5 small-cap impact stocks are making social change
- 3 Small Caps With Big Return Potential
- Alphabet slays its earnings but falls on its sword with cloud
- What is the Nikkei 225 index?
- There’s nothing artificial about NVIDIA’s relationship with AI
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.